Home » Topics » BioWorld Science

BioWorld Science
RSS

Shionogi licenses S-365598 to ViiV for use in ultra long-acting HIV regimens

Sep. 29, 2021

Intranasal subunit SARS-CoV-2 vaccines elicit mucosal and systemic immunity in vivo

Sep. 29, 2021

Targeting KIR3DS1/HLA-F axis as new therapeutic strategy against human adenovirus infections

Sep. 29, 2021

Assessing pharmacologic activity of PD(L)-1 MAb therapeutics in tumors by target pharmacodynamics

Sep. 29, 2021

New KDM1A inhibitors discovered at Shenyang Pharmaceutical University

Sep. 29, 2021

Cytomegalovirus DNA polymerase inhibitors discovered at the University of Alberta

Sep. 29, 2021

Peking University presents new boron-carrying agents

Sep. 29, 2021

Shanghai Zheye Biotechnology divulges G12C mutant GTPase KRAS inhibitors

Sep. 29, 2021

New humanized Col6a1-mutated knock-in mouse model of collagen VI-related muscular dystrophy

Sep. 29, 2021

Development of NTC-001, a first-in-class humanized antibody targeting CXCL1

Sep. 29, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...